{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:16:38Z","timestamp":1792718198230,"version":"4.5.0"},"reference-count":46,"publisher":"Xia & He Publishing","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,28]]},"DOI":"10.14218\/jcth.2020.00012","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T02:55:48Z","timestamp":1602816948000},"page":"1-5","source":"Crossref","is-referenced-by-count":58,"title":["Chronic Liver Disease and Silymarin: A Biochemical and Clinical Review"],"prefix":"10.14218","volume":"8","author":[{"given":"Sean P.","family":"Tighe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daud","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umair","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"key20201016025540_b1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/medicines6010041","article-title":"The epidemiology, risk profiling and diagnostic challenges of nonalcoholic fatty liver disease","volume":"6","author":"Iqbal","year":"2019","journal-title":"Medicines (Basel)"},{"key":"key20201016025540_b2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41395-018-0365-4","article-title":"Trends in chronic liver disease-related hospitalizations: A population-based study","volume":"114","author":"Asrani","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"key20201016025540_b3","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1053\/j.gastro.2018.07.008","article-title":"Changing trends in etiology-based annual mortality from chronic liver disease, from 2007 through 2016","volume":"155","author":"Kim","year":"2018","journal-title":"Gastroenterology"},{"key":"key20201016025540_b4","doi-asserted-by":"crossref","first-page":"107917","DOI":"10.1016\/j.drugalcdep.2020.107917","article-title":"The impact of chronic liver disease in patients receiving active pharmacological therapy for opioid use disorder: One-year findings from a prospective cohort study","volume":"209","author":"Dennis","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"key20201016025540_b5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1530-0277.2006.00063.x","article-title":"Silymarin protects against acute ethanol-induced hepatotoxicity in mice","volume":"30","author":"Song","year":"2006","journal-title":"Alcohol Clin Exp Res"},{"key":"key20201016025540_b6","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hep.510230415","article-title":"Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin","volume":"23","author":"Dehmlow","year":"1996","journal-title":"Hepatology"},{"key":"key20201016025540_b7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/diseases6030080","article-title":"Potential therapeutic benefits of herbs and supplements in patients with NAFLD","volume":"6","author":"Perumpail","year":"2018","journal-title":"Diseases"},{"key":"key20201016025540_b8","first-page":"105","article-title":"Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin","volume":"27","author":"Valenzuela","year":"1994","journal-title":"Biol Res"},{"key":"key20201016025540_b9","first-page":"239","article-title":"Reassessing bioavailability of silymarin","volume":"16","author":"Javed","year":"2011","journal-title":"Altern Med Rev"},{"key":"key20201016025540_b10","first-page":"614","article-title":"Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers","volume":"32","author":"Gatti","year":"1994","journal-title":"Int J Clin Pharmacol Ther"},{"key":"key20201016025540_b11","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1124\/dmd.111.040212","article-title":"Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C","volume":"39","author":"Schrieber","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"key20201016025540_b12","first-page":"219","article-title":"Randomized open study of the dose-effect relationship of a short course of IdB 1016 in patients with viral or alcoholic hepatitis","volume":"64","author":"Vailati","year":"1993","journal-title":"Fitoterapia"},{"key":"key20201016025540_b13","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1089\/jir.2017.0051","article-title":"High dose of silymarin in patients with decompensated liver disease: A randomized controlled trial","volume":"37","author":"Fathalah","year":"2017","journal-title":"J Interferon Cytokine Res"},{"key":"key20201016025540_b14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/CAD.0000000000000211","article-title":"Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review","volume":"26","author":"Mastron","year":"2015","journal-title":"Anticancer Drugs"},{"key":"key20201016025540_b15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.tiv.2007.11.020","article-title":"Assessment of drug-drug interaction for silymarin","volume":"22","author":"Doehmer","year":"2008","journal-title":"Toxicol In Vitro"},{"key":"key20201016025540_b16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1300\/J381v09n02_09","article-title":"Natural medicines comprehensive database","volume":"9","author":"Fazzi","year":"2008","journal-title":"J Consum Health Internet"},{"key":"key20201016025540_b17","first-page":"173","article-title":"Milk thistle for treatment of nonalcoholic fatty liver disease","volume":"11","author":"Abenavoli","year":"2011","journal-title":"Hepatitis Monthly"},{"key":"key20201016025540_b18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/antiox4010204","article-title":"Silymarin as a natural antioxidant: An overview of the current evidence and perspectives","volume":"4","author":"Surai","year":"2015","journal-title":"Antioxidants (Basel)"},{"key":"key20201016025540_b19","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3390\/nu9101086","article-title":"Silibinin restores NAD\u207a levels and induces the SIRT1\/AMPK pathway in non-alcoholic fatty liver","volume":"9","author":"Salomone","year":"2017","journal-title":"Nutrients"},{"key":"key20201016025540_b20","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14218\/JCTH.2019.00028","article-title":"Pathogenesis of insulin resistance and atherogenic dyslipidemia in nonalcoholic fatty liver disease","volume":"7","author":"Akhtar","year":"2019","journal-title":"J Clin Transl Hepatol"},{"key":"key20201016025540_b21","first-page":"1073","article-title":"Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD)","volume":"8","author":"Ni","year":"2016","journal-title":"Am J Transl Res"},{"key":"key20201016025540_b22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jep.2017.06.030","article-title":"Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation","volume":"208","author":"Cui","year":"2017","journal-title":"J Ethnopharmacol"},{"key":"key20201016025540_b23","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00004836-200310000-00013","article-title":"Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons","volume":"37","author":"Lieber","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"key20201016025540_b24","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jhep.2009.02.023","article-title":"Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells","volume":"50","author":"Trappoliere","year":"2009","journal-title":"J Hepatol"},{"key":"key20201016025540_b25","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.intimp.2013.08.019","article-title":"Silibinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1\/PI3K\/Akt pathway","volume":"17","author":"Zhang","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"key20201016025540_b26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fphar.2016.00345","article-title":"Silymarin ameliorates metabolic dysfunction associated with diet-induced obesity via activation of farnesyl X receptor","volume":"7","author":"Gu","year":"2016","journal-title":"Front Pharmacol"},{"key":"key20201016025540_b27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/molecules22020191","article-title":"Silymarin\/silybin and chronic liver disease: A marriage of many years","volume":"22","author":"Federico","year":"2017","journal-title":"Molecules"},{"key":"key20201016025540_b28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.freeradbiomed.2014.05.002","article-title":"Silybin exerts antioxidant effects and induces mitochondrial biogenesis in liver of rat with secondary biliary cirrhosis","volume":"73","author":"Serviddio","year":"2014","journal-title":"Free Radic Biol Med"},{"key":"key20201016025540_b29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/IJGM.S141111","article-title":"Clinical characteristics and outcome of toxicity from Amanita mushroom poisoning","volume":"10","author":"Trakulsrichai","year":"2017","journal-title":"Int J Gen Med"},{"key":"key20201016025540_b30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/1574887111666160724183409","article-title":"Alcoholic hepatitis: Pathogenesis, diagnosis and treatment","volume":"11","author":"Abenavoli","year":"2016","journal-title":"Rev Recent Clin Trials"},{"key":"key20201016025540_b31","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S1499-3872(16)60096-6","article-title":"Dietary supplementation in patients with alcoholic liver disease: a review on current evidence","volume":"15","author":"Ghorbani","year":"2016","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"key20201016025540_b32","doi-asserted-by":"crossref","first-page":"e9061","DOI":"10.1097\/MD.0000000000009061","article-title":"The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials","volume":"96","author":"Zhong","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"key20201016025540_b33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4254\/wjh.v5.i3.109","article-title":"Silymarin in non alcoholic fatty liver disease","volume":"5","author":"Cacciapuoti","year":"2013","journal-title":"World J Hepatol"},{"key":"key20201016025540_b34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/1574887109666141216110337","article-title":"Phytotherapy and NAFLD--from goals and challenges to clinical practice","volume":"9","author":"Milosevi\u0107","year":"2014","journal-title":"Rev Recent Clin Trials"},{"key":"key20201016025540_b35","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jama.2012.8265","article-title":"Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial","volume":"308","author":"Fried","year":"2012","journal-title":"JAMA"},{"key":"key20201016025540_b36","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.3748\/wjg.v23.i27.5004","article-title":"Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis","volume":"23","author":"de Avelar","year":"2017","journal-title":"World J Gastroenterol"},{"key":"key20201016025540_b37","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/hep.21347","article-title":"Global challenges in liver disease","volume":"44","author":"Williams","year":"2006","journal-title":"Hepatology"},{"key":"key20201016025540_b38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40816-018-0079-6","article-title":"Pharmacological influences of natural products as bioenhancers of silymarin against carbon tetrachloride-induced hepatotoxicity in rats","volume":"4","author":"Javed","year":"2018","journal-title":"Clin Phytosci"},{"key":"key20201016025540_b39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3350\/cmh.2015.21.1.49","article-title":"Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells","volume":"21","author":"Gu","year":"2015","journal-title":"Clin Mol Hepatol"},{"key":"key20201016025540_b40","first-page":"409","article-title":"Potential effect of garlic oil and silymarin on carbon tetrachloride-induced liver injury","volume":"6","author":"Wafay","year":"2012","journal-title":"Aust J Basic Appl Sci"},{"key":"key20201016025540_b41","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2893.2008.00971.x","article-title":"Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats","volume":"15","author":"Tsai","year":"2008","journal-title":"J Viral Hepat"},{"key":"key20201016025540_b42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/1567201052772870","article-title":"Comparative study of different silymarin formulations: formulation, characterisation and in vitro\/in vivo evaluation","volume":"2","author":"Abrol","year":"2005","journal-title":"Curr Drug Deliv"},{"key":"key20201016025540_b43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijpharm.2006.04.023","article-title":"Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performance","volume":"319","author":"El-Samaligy","year":"2006","journal-title":"Int J Pharm"},{"key":"key20201016025540_b44","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.phymed.2008.08.002","article-title":"Synergistic effect of silymarin and standardized extract of Phyllanthus amarus against CCl4-induced hepatotoxicity in Rattus norvegicus","volume":"15","author":"Yadav","year":"2008","journal-title":"Phytomedicine"},{"key":"key20201016025540_b45","first-page":"12","article-title":"Hep573 study: A randomised, double-blind, placebocontrolled trial of silymarin alone and combined with antioxidants to improve liver function and quality of life in people with chronic hepatitis C","volume":"30","author":"Salmond","year":"2018","journal-title":"Aust J Herb Naturop Med"},{"key":"key20201016025540_b46","first-page":"2569","article-title":"Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease","volume":"91","author":"Barbaro","year":"1996","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Clinical and Translational Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2020-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:19:24Z","timestamp":1783707564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2020-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,10,16]]},"published-print":{"date-parts":[[2020,12,28]]}},"alternative-id":["10.14218\/JCTH.2020.00012"],"URL":"https:\/\/doi.org\/10.14218\/jcth.2020.00012","relation":{},"ISSN":["2225-0719","2310-8819"],"issn-type":[{"value":"2225-0719","type":"print"},{"value":"2310-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]}}}